Spero will use the funding, raised from backers including Lundbeck, Merck and GlaxoSmithKline, to advance its anti-infectives pipeline.

US-based biopharmaceutical company Spero Therapeutics raised $30m today in a series A round led by Lundbeckfond Ventures, the corporate venturing unit for pharmaceutical firm Lundbeck.

MRL Ventures, a corporate venturing subsidiary of pharmaceutical company Merck, also took part in the round alongside SR One, the early-stage investment arm of pharmaceutical company GlaxoSmithKline, as well as investment holding firm The Kraft Group, Atlas Venture and Partners Innovation Fund.

Spero is developing treatments for bacterial infections based around its Potentiator programme, a…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?